Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
Curr Drug Targets. 2024 Apr 2. doi: 10.2174/0113894501290296240327081624. Online ahead of print.ABSTRACTDrug repurposing is an emerging approach to reassigning existing pre-approved therapies for new indications. The FDA Adverse Event Reporting System (FAERS) is a large database of over 28 million adverse event reports submitted by medical providers, patients, and drug manufacturers and provides extensive drug safety signal data. In this review, four common drug repurposing strategies using FAERS are described, including inverse signal detection for a single disease, drug-drug interactions that mitigate a target ADE, ident...
Source: Current Drug Targets - April 3, 2024 Category: Drugs & Pharmacology Authors: Robert Morris Feng Cheng Rahinatu Ali Source Type: research
Skin Microbial Composition and Genetic Mutation Analysis in Precision Medicine for Epidermolysis Bullosa
Curr Drug Targets. 2024 Apr 1. doi: 10.2174/0113894501290512240327091531. Online ahead of print.ABSTRACTEpidermolysis bullosa (EB) is an inherited skin disease representing a spectrum of rare genetic disorders. These conditions share the common trait that causes fragile skin, resulting in the development of blisters and erosions. The inheritance follows an autosomal pattern, and the array of clinical presentations leads to significant physical suffering, considerable morbidity, and mortality. Despite EB having no cure, effectively managing EB remains an exceptional challenge due to its rarity and complexity, occasionally c...
Source: Current Drug Targets - April 3, 2024 Category: Drugs & Pharmacology Authors: Inna Syafarina Maulida Mazaya Ariani Indrawati Sharfina Zahra Akbar Rifki Sadikin Caecilia Sukowati Source Type: research
Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
Curr Drug Targets. 2024 Apr 2. doi: 10.2174/0113894501290296240327081624. Online ahead of print.ABSTRACTDrug repurposing is an emerging approach to reassigning existing pre-approved therapies for new indications. The FDA Adverse Event Reporting System (FAERS) is a large database of over 28 million adverse event reports submitted by medical providers, patients, and drug manufacturers and provides extensive drug safety signal data. In this review, four common drug repurposing strategies using FAERS are described, including inverse signal detection for a single disease, drug-drug interactions that mitigate a target ADE, ident...
Source: Current Drug Targets - April 3, 2024 Category: Drugs & Pharmacology Authors: Robert Morris Feng Cheng Rahinatu Ali Source Type: research
Skin Microbial Composition and Genetic Mutation Analysis in Precision Medicine for Epidermolysis Bullosa
Curr Drug Targets. 2024 Apr 1. doi: 10.2174/0113894501290512240327091531. Online ahead of print.ABSTRACTEpidermolysis bullosa (EB) is an inherited skin disease representing a spectrum of rare genetic disorders. These conditions share the common trait that causes fragile skin, resulting in the development of blisters and erosions. The inheritance follows an autosomal pattern, and the array of clinical presentations leads to significant physical suffering, considerable morbidity, and mortality. Despite EB having no cure, effectively managing EB remains an exceptional challenge due to its rarity and complexity, occasionally c...
Source: Current Drug Targets - April 3, 2024 Category: Drugs & Pharmacology Authors: Inna Syafarina Maulida Mazaya Ariani Indrawati Sharfina Zahra Akbar Rifki Sadikin Caecilia Sukowati Source Type: research
Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
Curr Drug Targets. 2024 Apr 2. doi: 10.2174/0113894501290296240327081624. Online ahead of print.ABSTRACTDrug repurposing is an emerging approach to reassigning existing pre-approved therapies for new indications. The FDA Adverse Event Reporting System (FAERS) is a large database of over 28 million adverse event reports submitted by medical providers, patients, and drug manufacturers and provides extensive drug safety signal data. In this review, four common drug repurposing strategies using FAERS are described, including inverse signal detection for a single disease, drug-drug interactions that mitigate a target ADE, ident...
Source: Current Drug Targets - April 3, 2024 Category: Drugs & Pharmacology Authors: Robert Morris Feng Cheng Rahinatu Ali Source Type: research
Skin Microbial Composition and Genetic Mutation Analysis in Precision Medicine for Epidermolysis Bullosa
Curr Drug Targets. 2024 Apr 1. doi: 10.2174/0113894501290512240327091531. Online ahead of print.ABSTRACTEpidermolysis bullosa (EB) is an inherited skin disease representing a spectrum of rare genetic disorders. These conditions share the common trait that causes fragile skin, resulting in the development of blisters and erosions. The inheritance follows an autosomal pattern, and the array of clinical presentations leads to significant physical suffering, considerable morbidity, and mortality. Despite EB having no cure, effectively managing EB remains an exceptional challenge due to its rarity and complexity, occasionally c...
Source: Current Drug Targets - April 3, 2024 Category: Drugs & Pharmacology Authors: Inna Syafarina Maulida Mazaya Ariani Indrawati Sharfina Zahra Akbar Rifki Sadikin Caecilia Sukowati Source Type: research
Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
Curr Drug Targets. 2024 Apr 2. doi: 10.2174/0113894501290296240327081624. Online ahead of print.ABSTRACTDrug repurposing is an emerging approach to reassigning existing pre-approved therapies for new indications. The FDA Adverse Event Reporting System (FAERS) is a large database of over 28 million adverse event reports submitted by medical providers, patients, and drug manufacturers and provides extensive drug safety signal data. In this review, four common drug repurposing strategies using FAERS are described, including inverse signal detection for a single disease, drug-drug interactions that mitigate a target ADE, ident...
Source: Current Drug Targets - April 3, 2024 Category: Drugs & Pharmacology Authors: Robert Morris Feng Cheng Rahinatu Ali Source Type: research
Skin Microbial Composition and Genetic Mutation Analysis in Precision Medicine for Epidermolysis Bullosa
Curr Drug Targets. 2024 Apr 1. doi: 10.2174/0113894501290512240327091531. Online ahead of print.ABSTRACTEpidermolysis bullosa (EB) is an inherited skin disease representing a spectrum of rare genetic disorders. These conditions share the common trait that causes fragile skin, resulting in the development of blisters and erosions. The inheritance follows an autosomal pattern, and the array of clinical presentations leads to significant physical suffering, considerable morbidity, and mortality. Despite EB having no cure, effectively managing EB remains an exceptional challenge due to its rarity and complexity, occasionally c...
Source: Current Drug Targets - April 3, 2024 Category: Drugs & Pharmacology Authors: Inna Syafarina Maulida Mazaya Ariani Indrawati Sharfina Zahra Akbar Rifki Sadikin Caecilia Sukowati Source Type: research
Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
Curr Drug Targets. 2024 Apr 2. doi: 10.2174/0113894501290296240327081624. Online ahead of print.ABSTRACTDrug repurposing is an emerging approach to reassigning existing pre-approved therapies for new indications. The FDA Adverse Event Reporting System (FAERS) is a large database of over 28 million adverse event reports submitted by medical providers, patients, and drug manufacturers and provides extensive drug safety signal data. In this review, four common drug repurposing strategies using FAERS are described, including inverse signal detection for a single disease, drug-drug interactions that mitigate a target ADE, ident...
Source: Current Drug Targets - April 3, 2024 Category: Drugs & Pharmacology Authors: Robert Morris Feng Cheng Rahinatu Ali Source Type: research
Genetic Factors and MicroRNAs in the Development of Gallbladder Cancer: The Prospective Clinical Targets
Curr Drug Targets. 2024 Mar 27. doi: 10.2174/0113894501182288240319074330. Online ahead of print.ABSTRACTGallbladder cancer (GBC) is an uncommon condition in which malignant (cancer) cells are detected in gallbladder tissue. Cancer is often triggered when normal cells turn malignant and begin to spread. Cancer can also be caused by genetic anomalies that result in uncontrolled cell proliferation and tumor development. MicroRNAs (also known as miRNAs or miRs) are a group of small, endogenous, non-coding RNAs of 19-23 nucleotides in length, which play a key role in post-transcriptional gene regulation. These miRNAs serve as ...
Source: Current Drug Targets - March 28, 2024 Category: Drugs & Pharmacology Authors: Roshani Quraishi Medha Dwivedi Monika Moitra Somali Sanyal Manish Dwivedi Source Type: research
Genetic Factors and MicroRNAs in the Development of Gallbladder Cancer: The Prospective Clinical Targets
Curr Drug Targets. 2024 Mar 27. doi: 10.2174/0113894501182288240319074330. Online ahead of print.ABSTRACTGallbladder cancer (GBC) is an uncommon condition in which malignant (cancer) cells are detected in gallbladder tissue. Cancer is often triggered when normal cells turn malignant and begin to spread. Cancer can also be caused by genetic anomalies that result in uncontrolled cell proliferation and tumor development. MicroRNAs (also known as miRNAs or miRs) are a group of small, endogenous, non-coding RNAs of 19-23 nucleotides in length, which play a key role in post-transcriptional gene regulation. These miRNAs serve as ...
Source: Current Drug Targets - March 28, 2024 Category: Drugs & Pharmacology Authors: Roshani Quraishi Medha Dwivedi Monika Moitra Somali Sanyal Manish Dwivedi Source Type: research
Genetic Factors and MicroRNAs in the Development of Gallbladder Cancer: The Prospective Clinical Targets
Curr Drug Targets. 2024 Mar 27. doi: 10.2174/0113894501182288240319074330. Online ahead of print.ABSTRACTGallbladder cancer (GBC) is an uncommon condition in which malignant (cancer) cells are detected in gallbladder tissue. Cancer is often triggered when normal cells turn malignant and begin to spread. Cancer can also be caused by genetic anomalies that result in uncontrolled cell proliferation and tumor development. MicroRNAs (also known as miRNAs or miRs) are a group of small, endogenous, non-coding RNAs of 19-23 nucleotides in length, which play a key role in post-transcriptional gene regulation. These miRNAs serve as ...
Source: Current Drug Targets - March 28, 2024 Category: Drugs & Pharmacology Authors: Roshani Quraishi Medha Dwivedi Monika Moitra Somali Sanyal Manish Dwivedi Source Type: research
Genetic Factors and MicroRNAs in the Development of Gallbladder Cancer: The Prospective Clinical Targets
Curr Drug Targets. 2024 Mar 27. doi: 10.2174/0113894501182288240319074330. Online ahead of print.ABSTRACTGallbladder cancer (GBC) is an uncommon condition in which malignant (cancer) cells are detected in gallbladder tissue. Cancer is often triggered when normal cells turn malignant and begin to spread. Cancer can also be caused by genetic anomalies that result in uncontrolled cell proliferation and tumor development. MicroRNAs (also known as miRNAs or miRs) are a group of small, endogenous, non-coding RNAs of 19-23 nucleotides in length, which play a key role in post-transcriptional gene regulation. These miRNAs serve as ...
Source: Current Drug Targets - March 28, 2024 Category: Drugs & Pharmacology Authors: Roshani Quraishi Medha Dwivedi Monika Moitra Somali Sanyal Manish Dwivedi Source Type: research
Genetic Factors and MicroRNAs in the Development of Gallbladder Cancer: The Prospective Clinical Targets
Curr Drug Targets. 2024 Mar 27. doi: 10.2174/0113894501182288240319074330. Online ahead of print.ABSTRACTGallbladder cancer (GBC) is an uncommon condition in which malignant (cancer) cells are detected in gallbladder tissue. Cancer is often triggered when normal cells turn malignant and begin to spread. Cancer can also be caused by genetic anomalies that result in uncontrolled cell proliferation and tumor development. MicroRNAs (also known as miRNAs or miRs) are a group of small, endogenous, non-coding RNAs of 19-23 nucleotides in length, which play a key role in post-transcriptional gene regulation. These miRNAs serve as ...
Source: Current Drug Targets - March 28, 2024 Category: Drugs & Pharmacology Authors: Roshani Quraishi Medha Dwivedi Monika Moitra Somali Sanyal Manish Dwivedi Source Type: research
An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis
The objective of this review is to clarify the different treatment options currently available or being investigated in clinical trials for managing scalp psoriasis.PMID:38500274 | DOI:10.2174/0113894501292755240304063020 (Source: Current Drug Targets)
Source: Current Drug Targets - March 19, 2024 Category: Drugs & Pharmacology Authors: Bindu Soni Riya Shivgotra Karan Trehan Aashveen Chhina Muskaan Saini Subheet Kumar Jain Shubham Thakur Source Type: research
